In a phase I trial of the EZH2 inhibitor tazemetostat, children with INI1-deficient tumors—including relapsed or refractory malignant rhabdoid tumors, atypical teratoid rhabdoid tumors, epithelioid sarcomas, and poorly differentiated chordomas—responded well to treatment, with some experiencing durable responses.
from Cancer via ola Kala on Inoreader http://ift.tt/2CRE060
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου